# Tesamorelin References: The Cited Trial and Safety Record

> Tesamorelin references — the full citation list behind every figure on this site, with DOIs and PubMed links: the pivotal NEJM and JAMA RCTs, the PK-PD model, LiverTox, and the 2026 meta-analysis.

Every figure logged on this site resolves to a source here — the pivotal RCTs, the mechanistic and PK studies, the regulatory and safety monographs, and the most recent meta-analysis.

## How to read this index

Each numbered entry corresponds to the inline [N] markers used across the site. Where a DOI or PubMed identifier exists, it is given so any claim can be traced to its primary source. Trials in HIV-associated lipodystrophy are the backbone of the record; the regulatory and pharmacokinetic sources are listed alongside them. The full citation list is reproduced below.

## References

[1] Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. https://pubmed.ncbi.nlm.nih.gov/18057338/
[2] Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. https://pubmed.ncbi.nlm.nih.gov/18690162/
[3] Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. https://pubmed.ncbi.nlm.nih.gov/25038357/
[4] Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. https://pubmed.ncbi.nlm.nih.gov/20943777/
[5] National Institute of Diabetes and Digestive and Kidney Diseases. Tesamorelin. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): NCBI Bookshelf (NIH); 2018. https://www.ncbi.nlm.nih.gov/books/NBK548730/
[6] Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-322. https://pubmed.ncbi.nlm.nih.gov/20101189/
[7] Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012;54(11):1642-1651. https://pubmed.ncbi.nlm.nih.gov/22495074/
[8] Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS. 2011;25(10):1281-1288. https://pubmed.ncbi.nlm.nih.gov/21516030/
[9] Lake JE, La K, Erlandson KM, Adrian S, Yenokyan G, Scherzinger A, Dube MP, Stanley T, Grinspoon S, Falutz J, Mamputu JC, Marsolais C, McComsey GA, Brown TT. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS. 2021;35(9):1395-1402. https://pubmed.ncbi.nlm.nih.gov/33756511/
[10] Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B. Predictors of treatment response to tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. PLoS One. 2015;10(10):e0140358. https://pubmed.ncbi.nlm.nih.gov/26457580/
[11] Gonzalez-Sales M, Barriere O, Tremblay PO, Nekka F, Mamputu JC, Boudreault S, Tanguay M. Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects. J Pharmacokinet Pharmacodyn. 2015;42(3):287-299. https://pubmed.ncbi.nlm.nih.gov/25895899/
[12] Rahman F, McLaughlin T, Mesquita P, Morin J, Potvin D, De Chantal M, Aberg JA. Effect of tesamorelin in people with HIV with and without dorsocervical fat: post hoc analysis of phase III double-blind placebo-controlled trial. J Clin Transl Sci. 2023;7(1):e40. https://pubmed.ncbi.nlm.nih.gov/36845310/
[13] Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026. https://pubmed.ncbi.nlm.nih.gov/41545261/
[14] Arora G, Conde KR, Desouza CV. Pharmacologic treatments for the preservation of lean body mass during weight loss. J Clin Med. 2026;15(2):541. https://pubmed.ncbi.nlm.nih.gov/41598480/
[15] Mayfield CK, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41476424/

---

A terminal trace of the peer-reviewed tesamorelin record — every visceral-fat and IGF-1 figure returned green and sourced, the HIV-lipodystrophy-only scope and the reverts-when-you-stop caveat printed beside the value, never behind it; no clinic at this prompt and nothing here dosed, dispensed, or sold.